ClearPoint Neuro, Inc. filed a Form S-3 shelf registration statement with the U.S. Securities and Exchange Commission on November 18, 2026, covering up to $200,000,000 in securities and including an at-the-market equity offering program of up to $100,000,000.
Key Highlights
- Maximum shelf offering: ClearPoint Neuro registered up to $200,000,000 in common stock, preferred stock, warrants, debt securities, and/or units under the base prospectus.
- ATM program included: A prospectus supplement covers up to $100,000,000 of common stock under an At-The-Market Equity Offering Sales Agreement with Stifel, Nicolaus & Company, Incorporated, originally dated November 7, 2024, as amended November 18, 2026.
- Unsold securities carried forward: $76,779,531.60 in unsold securities from the prior Form S-3 (File No. 333-275476), originally filed November 9, 2023 and declared effective November 20, 2023, are being rolled into this registration statement under Rule 415(a)(6); the prior filing fee carried forward was $11,332.66.
- Last reported share price: On November 17, 2026, the last reported sale price of the company's common stock was $7.86 per share, according to the filing.
- Filer classification: The registrant identified itself as a non-accelerated filer and a smaller reporting company.
- Listing: The common stock is listed on NASDAQ:CLPT under the symbol "CLPT" on The Nasdaq Capital Market.
ClearPoint Neuro's November 2026 Shelf Registration: Structure and Key Terms
ClearPoint Neuro, Inc. submitted a Form S-3 registration statement to the SEC on November 18, 2026, establishing a new shelf facility that the company disclosed would allow it to offer and sell up to $200,000,000 in securities "from time to time, in one or more series or issuances and on terms that we will determine at the time of the offering." The securities covered include common stock, preferred stock, warrants, debt securities, and units representing combinations of two or more of those security types.
The registration statement contains two prospectuses. The base prospectus covers the full $200,000,000 shelf. A separate prospectus supplement addresses up to $100,000,000 of common stock available through an at-the-market equity offering program under a Sales Agreement with Stifel, Nicolaus & Company, Incorporated. According to the filing, the $100,000,000 covered by the prospectus supplement is included within, and not in addition to, the $200,000,000 base shelf. Any portion of the ATM amount not sold remains available for other offerings under the base prospectus.
The filing also carries forward $76,779,531.60 in unsold securities from the company's prior shelf registration (File No. 333-275476), which was declared effective on November 20, 2023. Under Rule 415(a)(6), the prior registration's filing fee of $11,332.66 associated with those unsold securities is being applied to this new registration statement. The filing states that the prior registration's offering of the unsold securities "will be deemed terminated as of the date of effectiveness of this registration statement." The company noted that if any of the unsold securities are sold under the prior registration between the initial filing date and the effective date of the new statement, it will file a pre-effective amendment to reduce the unsold securities amount accordingly.
What Was Disclosed
ClearPoint Neuro filed a Form S-3 shelf registration on November 18, 2026, registering up to $200,000,000 in mixed securities, including a $100,000,000 ATM program with Stifel, Nicolaus & Company, and rolling forward $76,779,531.60 in unsold securities from a 2023 shelf registration.




Please wait processing your request...